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almost tripled, which is the largest growth rate of any 
medical specialty in that period. This development has 
strengthened the standing of medical physics and radiation 
oncology in the hospitals. However, it has also been 
recognized that the growth in expenditure has not come with 
an increase in patient volume or corresponding outcome 
improvements. More recently the trend has reversed due in 
part to the overall economical situation and the healthcare 
reform. Cutting cost is the new theme. The research in 
medical physics has been hit particularly hard by this 
development. The budget and time for research is being cut. 
Funding from government agencies is increasingly harder to 
get. The trend to more "professionalism" in medical physics 
with mandatory physics residencies has shifted the focus 
further away from research. 
In this presentation we will report on our efforts within the 
American Association of Physicists in Medicine (AAPM) 
Working Group FUTURE (FUTURE of Research and Academic 
Training) to put medical physics research back on the map. 
WG FUTURE activities include the definition of research 
activity roadmaps, organization of "Expanding Horizons" 
meetings to open doors for medical physics research outside 
of radiation oncology, support of students aspiring a research 
career in medical physics, and reaching out to similar 
activities elsewhere in the world.  
We will also report on our own challenges of developing and 
maintaining a vibrant research environment in academic 
medical physics (at the University of Madison, Wisconsin) at 
in a hospital environment (Massachusetts General Hospital).  
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Medical physics research in a hospital department  
N. Jornet1 
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I would like to start by adding "small" and "clinical" to the 
title. It would then read research in a small clinical Medical 
Physics Department. Two things to define: research and 
small. Let’s start with research. Research is “serious study of 
a subject that is intended to discover new facts or test new 
ideas”. Small applied to a Medial Physics Department is more 
difficult to define but everybody would agree that a staff of 6 
physicists, 6 RTT, 3 residents and 1 secretary to give service 
to Radiation Oncology, Nuclear Medicine, Imaging and 
Radiation Protection is not BIG. This describes the 
department in which I am working in. Now, the question: Can 
such a Department do any Research? And if so how this can 
happen? Four clues:  
1. Optimize QA to get the time.Time is needed to think, to 
get inspired in order to choose the subject of your research. 
2. Don’t wait to see if you become BIG to start. It may never 
happen. 
3. Link to other departments in the hospital, link to other 
Medical Physics departments in your city, departments at the 
Universities. This will enlarge your human resources and you 
will increase expertise in your group and also have different 
and interesting angles to your research topic. 
4. Inspiration. Think outside the box. Take risks! 
By doing this I think that you can study a subject and discover 
new facts or test new ideas. This is RESEARCH. It requires 
effort and enthusiasm, research is fun. Being small does not 
mean that you can’t think BIG.  
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The number of facilities proton therapy is increasing around 
the world. The benefit of delivering radiation treatment with 
protons as compared to photons is the reduced integral dose 
due to the protons stopping inside the patient and delivering 
a high dose at the end of their range. This leads to highly 
conformal dose distributions with sharp dose gradients, both 
laterally as well as at the distal end of a proton treatment 
field. The distal high dose gradients make accurate dose 
calculations for proton therapy even more important than for 
photon therapy. A slight underestimation in proton range can 
lead to unirradiated sections of the target region.  
Clinical dose calculations are generally performed using 
analytical algorithms, often referred to as pencil-beam 
algorithms, which propagate protons through the patient 
geometry. Each field is composed of ‘pencils’ which are 
separated into a central axis part combined with a Gaussian 
fluence map to account for the lateral beam spread. The 
main advantage of this approach is its computational speed. 
More accurate dose calculation algorithms such as Monte 
Carlo (MC) simulations are available but have not yet 
translated into clinical routine for proton therapy treatment 
planning due to lengthly calculation times. MC simulations 
are, however, frequently used to estimate the accuracy of 
analytical dose calculation algorithms.  
Analytical algorithms generally fail to describe the effects of 
multiple Coulomb-scattering of protons. These effects are 
particularly important along high-density interfaces along the 
treatment field direction. Incorrect modeling of scattering 
can result in distortions of the delivered dose distributions. 
This can effect both the range of the proton field as well as 
the delivered dose distribution. Both effects will be discussed 
through comparisons between MC simulations and analytical 
dose calculations. We investigated the validity of range 
margins to compensate for range uncertainties and the 
clinical impact of dose calculation approximations. 
In a site-specific analysis looking at 10-24 patients for 7 
treatment sites, we find that for liver, prostate and whole 
brain fields a reduction of currently used uncertainty margins 
is feasible even without introducing MC dose calculations. 
Accounting for uncertainties from dose calculation algorithms 
we recommend a reduction of these margins to 2.8% + 1.2 
mm for liver and prostate treatments and 3.1% + 1.2 mm for 
whole brain treatments, respectively. For some breast, lung 
and head & neck patients dose calculations current range 
margins are found to be insufficient, at least if used 
generically. We recommend a generic margin of 6.3% + 1.2 
mm for breast, lung and head & neck treatments if no case 
specific adjustments are applied. Thus, currently used 
generic range uncertainty margins in proton therapy should 
be redefined in a site-specific manner and complex 
geometries may require a field specific adjustment.  
For a dosimetric analysis of clinical used properties in a study 
containing 10 patients per site for 5 treatment sites, we find 
that target doses obtained with analytical dose calculation 
methods are, on average, 1-2% higher compared to those 
calculated with MC simulations. Both calculation methods 
agree within 5% for the mean dose, and the dose values 
covering 95%, 50% and 2% of the target volume. A γ-index 
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passing rate for target volumes was found to be above 96% 
for a 3%/3mm criteria. Differences in tumor control 
probability were within 2.5% for liver and breast, however, 
for head-and-neck and prostate patients the differences were 
up to 6.5% and up to 11% for lung patients. 
We conclude that approximations introduced in analytical 
dose calculation methods can result in significant range 
uncertainties for heterogeneous patient geometries or 
introduce a systematically reduced dose in target volumes. 
Routine MC simulations for treatment planning or verification 
may be necessary to ensure full target coverage to the 
prescribed dose levels.  In particular for clinical trials 
comparing photon vs. proton treatments, MC simulations may 
be required to avoid bias due to differences in dose 
calculations. 
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This talk describes the reference dosimetry of clinical proton 
beams. The main goal is to clarify the application of the IAEA 
TRS-398 dosimetry Code of Practice to modern proton beam 
delivery systems. A clear distinction is made between (i) 
those proton beam delivery systems that should be calibrated 
with an SOBP field, and (ii) those delivery systems that 
should be calibrated with a mono-energetic field. For these 
second type of delivery systems, a word of caution is issued 
on the use of cylindrical ionisation chambers. Contrary to the 
IAEA TRS-398 recommendations, this talk presents different 
arguments in favour of taking the effective point of 
measurement of cylindrical chambers into account when 
positioning the reference point of the chamber at the 
measurement depth. Finally, this talk also discusses the 
comparison between reference dosimetry and other 
independent dosimetry techniques, such as Faraday cup 
dosimetry and water calorimetry. 
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The finite range of protons makes the delivered dose 
distribution, particularly in case of IMPT, very sensitive to 
any uncertainty and change in patient anatomy. In the best 
case, the patient anatomy and the treatment plans are 
robust over the entire treatment course such that treatment 
adaptation is not necessary. Adaptive therapy is, however, 
not simply a buzz-word, especially not for the relatively new 
indications for proton therapy in the thoracic and pelvic 
region. Existing and new proton therapy centers are working 
towards a framework that allows them to 
1) determine which patients will benefit from a treatment 
adaptation. 
2) efficiently adapt and validate the treatment plan. 
The tools for such a framework are; volumetric image-
guidance, dose-recalculation and accumulation, and plan-
reoptimization. This presentation will discuss the needs for 
these tools, their availability and integration, and the current 
reality in plan adaptation in proton therapy. 
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The benefit of intensity-modulated radiation therapy (IMRT) 
in the treatment of head-and-neck cancer (HNC) has been 
demonstrated in numerous studies. Highly conformal 
radiation allows for a high dose to high-risk areas, whilst 
sparing adjacent organs at risk (OAR) such as the parotid 
glands. Clinical studies have shown that IMRT reduces grade-3 
xerostomia in comparison to three-dimensional conformal 
radiotherapy. The next step is to develop dose-escalation 
studies, that so called “Dose painting”. Dose-painting IMRT is 
aimed at exploiting inhomogeneous dose distributions 
adapted to tumor heterogeneity. Tumor regions of increased 
radiation resistance receive escalated dose levels, whereas 
radiation-sensitive regions receive conventional or even de-
escalated dose levels. Dose painting relies on biologic 
imaging. On the other hand, the changes to the dose 
distribution during treatment based on specific  patients 
variations due to weight loss and tumor shrink must be 
corrected. For that purpose Adaptative Radiotherapy is 
developed. This is done by means of:  
a)  Image guided RT: Repositioning of the patient at the time 
of treatment  
b)  Dose tracking: Computiong fraction dose based on daily 
cone-beam CT, accumulating dose by deformable registration 
and evaluating the accumulated dose at different organs 
c)  Replanning: Adapt the dose to a systematic volumentric 
changes and compensate for undesired dose accumulation. 
We will review the whole process and we will discuss the 
clinical data published and some of the new trials that are 
under evaluation. 
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Radiotherapy is an integral part of soft tissue sarcoma (STS) 
multidisciplinary management, with local control in excess of 
90 % for disease arising in the extremities. 
From our recently published Phase 2 study of preoperative 
image-guided intensity modulated radiation therapy (IG-
IMRT) to reduce wound and combined modality morbidities 
in lower extremity soft tissue sarcoma (LE-STS), 
approximately 20 % of the patient population required 
replanning during their course of radiation therapy (RT) due 
to soft tissue/tumour volume changes exceeding 1 cm as 
measured on daily cone beam CT localization used for RT 
guidance.   
Previous work evaluated the dosimetric effect of tumour 
volume changes (TVC) for preoperative IMRT of LE-STS to 
determine critical indicators, as measured on daily CBCT 
localization, to motivate plan adaptation.  We found that a 1 
cm TVC deviation on CBCT imaging was a reliable threshold 
